SirReal2
(Synonyms: 乙酰胺,2-[(4,6-二甲基-2-嘧啶基)硫]-N-[5-(1-萘甲基)-2-噻唑]-) 目录号 : GC13942A selective SIRT2 inhibitor
Cas No.:709002-46-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Target: Sirtuin 2 (Sirt2)
IC50: 140 nM
SirReal2 is a potent and selective Sirtuin 2 (Sirt2) inhibitor with IC50 value of 140 nM [1]. The Sirtuins are a highly conserved class of NAD+-dependent lysine deacylases. The human isotype Sirtuin 2 (Sirt2) deacetylates both cytoplasmatic and nuclear proteins and it has been implicated in the pathogenesis of cancer, neurodegeneration, and inflammation [1, 2]. Therefore, the modulation of Sirt2 activity is a promising strategy for pharmaceutical intervention.
In vitro: SirReal2, the most potent Sirtuin-rearranging ligand, induced the checkpoint protein BubR1 destabilization and hyperacetylation of the microtubule network in HeLa cells [1]. Moreover, SirReal2 (20 μM) inhibited Sirt2 activity but was unable to affect the activity of the other Class-I sirtuins Sirt1 and Sirt3 in cells. SirReal2 (12.5, 25, and 50 μM) treatment dose-dependently induced depletion of BubR1 but did not alter cell cycle distribution [1].
In vivo: SirReal2 (12.5, 25, and 50 μM) treatment did not induce the increase in acetylation of p53 [1].
References:
1. Rumpf T, Schiedel M, Karaman B, Roessler C, North BJ, Lehotzky A, et al. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat Commun. 2015;6:6263. Epub 2015/02/13.
2. Galleano I, Schiedel M, Jung M, Madsen AS, Olsen CA. A Continuous, Fluorogenic Sirtuin 2 Deacylase Assay: Substrate Screening and Inhibitor Evaluation. J Med Chem. 2016;59(3):1021-31. Epub 2016/01/21.
Cas No. | 709002-46-0 | SDF | |
别名 | 乙酰胺,2-[(4,6-二甲基-2-嘧啶基)硫]-N-[5-(1-萘甲基)-2-噻唑]- | ||
化学名 | 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-(5-(naphthalen-1-ylmethyl)thiazol-2-yl)acetamide | ||
Canonical SMILES | O=C(CSC1=NC(C)=CC(C)=N1)NC2=NC=C(S2)CC3=CC=CC4=CC=CC=C43 | ||
分子式 | C22H20N4OS2 | 分子量 | 420.55 |
溶解度 | ≥ 14.71mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3778 mL | 11.8892 mL | 23.7784 mL |
5 mM | 0.4756 mL | 2.3778 mL | 4.7557 mL |
10 mM | 0.2378 mL | 1.1889 mL | 2.3778 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。